GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 77, No. 13_Supplement ( 2017-07-01), p. 5608-5608
    Abstract: Introduction: Protein tyrosine phosphatases (PTPs) are important regulators of signal transduction in immune cells. While most analytical methods focus on the detection of these crucial enzymes at the RNA or protein level, a method was lacking to monitor multiple enzymatic activities in patient-derived materials like blood and (tumor) tissues. Such a substrate-specific assay is a new tool for biomarker discovery in immuno-oncology (I-O), because the I-O targets - checkpoint and immune receptors like PD1, CTLA4, LAG3, 4-1BB, CD40, CD20, OX40, TIGIT and GITR - are controlled by phosphatases. The aim of this study was to develop a multiplex PTP assay and investigate the phosphatase activity in metastatic renal cell carcinoma (mRCC) tissues with high and low levels of TILs (tumor-infiltrating lymphocytes). Methods: On the basis of hematoxylin and eosin staining of mRCC tissues, 9 tissues with high TILS-scores were selected, as well as 10 tissues without TILS, matched on basis of the percentage of viable tumor cells. The technology used is a second generation peptide microarray, which is fully automated with short turnaround times and a high throughput of clinical samples in a 96-well setup. Arrays comprise 46 unique nitrophosphotyrosine containing peptides derived from known phosphosites. When a clinical sample is applied to this peptide microarray, this will lead to a pattern of peptide dephosphorylations, which is monitored in real time (kinetic readout). Results: The PTP assay was first developed for PBMC profiling. 0.10 ug protein/array was used, corresponding to 10000 cells. The signals were concentration dependent and could be inhibited by PTP inhibitors. For tissue profiling 2.0 µg protein input (0.02 mm3 tissue) was used. A 2-group comparison analysis of the phosphatase activity in tissues with high scores of TILs (massive infiltration, N=9) vs. without (N=10), revealed that 29 of 46 peptide substrates showed significantly higher dephosphorylation (PTP) activities in the tissues with high levels of lymphocyte infiltrates. A PCA revealed a clear separation between the groups of high and low TILS scores. Discriminating phosphosites (p & lt;0.0002) were derived from the following 10 signaling proteins RET, ERBB2, PAXI, PGFRB, CBL, FRK, PDPK1, INSR, PECA1 and the T-cell kinase LCK. Conclusions: Proof of concept was shown in mRCC samples that high PTP activity correlates with high levels of TILS. As a TILS-score itself is already regarded to be a candidate biomarker for I-O therapy response, the observed correlation is a basis for the development of more mechanistic biomarkers predicting therapy response. This method can be a starting point for the development of an enzymatic and thus sensitive and quantitative TILS test. This study has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no 259939. Citation Format: Rob Ruijtenbeek, Liesbeth Houkes-van Kerkhoff, Jeannette Oosterwijk, Liesbeth Hovestad-Bijl1, Riet Hilhorst, Alejandro H. Gomez, Juan F. Rodriguez, Jesus Garcia-Donas, Bart Kiemeney, Egbert Oosterwijk. Correlation of phosphatase activity with lymphocyte infiltrates in metastatic renal cell carcinoma tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5608. doi:10.1158/1538-7445.AM2017-5608
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2017
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Impact, Science Impact, Ltd., Vol. 2018, No. 2 ( 2018-03-29), p. 15-17
    Type of Medium: Online Resource
    ISSN: 2398-7073
    Language: English
    Publisher: Science Impact, Ltd.
    Publication Date: 2018
    detail.hit.zdb_id: 2964345-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 75, No. 15_Supplement ( 2015-08-01), p. 2419-2419
    Abstract: Introduction: Sunitinib, a potent multitargeted receptor tyrosine kinase inhibitor, is the first line treatment for metastatic renal cell carcinoma (mRCC). Because sunitinib responses and toxicity are highly variable, there is a need for biomarkers predicting sunitinib response or predicting the optimal sequence preference when using alternative tyrosine kinase inhibitors. The aim of this study was to investigate the correlation between ex vivo drug response and clinical response in renal cell carcinoma (RCC) and to explore alternative treatment options. This study has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no 259939. Methods: Protein tyrosine kinase activity profiles were generated on PamChip® peptide microarrays of lysed tumor resection tissues (1-5mm3) from 22 mRCC patients. The ex vivo effect of kinase inhibitors (sunitinib, axitinib, sorafenib, pazopanib, erlotinib and crenolanib) was determined and analyzed with Bionavigator software. A two-group (sunitinib responders versus non-responders) comparison applied on the inhibition ratios identified the significantly different peptide phosphorylations. Peptides were clustered according to their correlation with clinical response. Results: As little as 5 μg protein input (0.05 mm3 tissue) was used per kinase activity profile. The ex vivo sunitinib effect positively correlated with clinical responses especially in the subgroup which received sunitinib as 1st line treatment (4 responders vs. 4 non-responders). 18 of the 105 peptides were significantly (p & lt;0.05) less phosphorylated upon ex vivo sunitinib treatment in 4 responders compared to 4 non-responders. Pathway analysis of the peptide phosphorylation patterns revealed sunitinib target involvement. Ex vivo erlotinib, axitinib or crenolanib showed reversed inhibition patterns i.e. more inhibition in the non-responder than in the responder group. In summary, we have shown that predicting clinical response to sunitinib based on the ex vivo response to sunitinib is feasible. This requires further investigation with a larger sample set. Furthermore, the ex vivo response to a drug panel suggests that identification of novel treatment options for non-responders might be feasible. Citation Format: Rob Ruijtenbeek, Liesbeth Houkes-van Kerkhoff, Maria Hilhorst, Peter Mulders, Jeannette Oosterwijk-Wakka, Lambertus Kiemeney, Egbert Oosterwijk. Predicting clinical response based on ex vivo drug response in renal cell carcinoma using kinase activity profiling. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2419. doi:10.1158/1538-7445.AM2015-2419
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2015
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Research Vol. 70, No. 8_Supplement ( 2010-04-15), p. 797-797
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 797-797
    Abstract: Introduction: Many new anti-cancer drugs target kinase activity. Unfortunately, methods to monitor the drug effects at the enzymatic level in patient derived tumor tissue are lacking. Here, a novel molecular profiling method for application in biomarker discovery is presented. This method is based on measuring kinase activities in tumor tissue extracts, and involves assessment of inhibition by a drug of interest. This ex vivo activity-based approach is enabled by dynamic peptide microarrays. These arrays comprise of peptides, which are known substrates for phosphorylation by protein kinases. Here we investigated the applicability of this approach in the classification of multiple tumors of different origin. Method: Patient-derived fresh frozen tissues of different tumor types (24 breast cancer (BC), 14 non-small cell lung cancer (NSCLC), 12 renal cell carcinomas (RCC)) were used for extraction of total protein in lysis buffer. Dependent on the tissue source, 6 slices of 10 µm were sufficient for 20-100 microarray analyses. Equal amounts of total protein were analyzed for kinase activity on dynamic PamChip peptide microarrays. These arrays comprised 144 or 256 different peptides. A PamChip96 plate format was used, enabling 96 microarray incubations per run. Protein amounts ranging from 1 − 5 µg were used per microarray analysis. Tumor extracts were analysed in the presence and absence of kinase inhibitor drugs (RCC: sorafenib and sunitinib, NSCLC: gefitinib). Results: We show here that from different tumors kinase activity profiles could be generated reproducibly (10-15% CV for selected peptides). Control experiments showed protein concentration and ATP dependency. In the RCC experiments different phosphorylation profiles were obtained when the non-tumor tissue was compared to tumor tissue derived from the same patient, showing higher kinase activities in the latter. In addition, inhibitor dependent modulation of the peptide phosphorylations was observed (sorafenib vs. sunitinib). Furthermore, differential kinase activity profiles were obtained that could be correlated to different patient subgroups (BC) or clinical data (long vs. short term survivors; NSCLC). Conclusion: A novel molecular profiling approach was successfully applied for classification of different tumors. This approach is based on detection of kinase activities as well as inhibition of kinase activity in tumor tissues. Application of this method in the discovery of biomarkers for diagnosis, prognosis or prediction of drug response is foreseen. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 797.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Analytical Biochemistry, Elsevier BV, Vol. 387, No. 2 ( 2009-04), p. 150-161
    Type of Medium: Online Resource
    ISSN: 0003-2697
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2009
    detail.hit.zdb_id: 1461105-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 4113-4113
    Abstract: Background: Reliable diagnostic tests are needed to identify early stage non-small cell lung carcinoma (NSCLC) patients with poor prognosis. Concomitantly there is a clear need for tests that enable the selection of patients who will benefit from targeted therapy with kinase inhibitors. We evaluated kinase activity profiles in two groups of early stage NSCLC patients, either for prognosis of long- or short-term survival, or for predicting erlotinib drug response. Method: Retrospective studies were performed on fresh frozen resection material of two groups of early stage NSCLC patients. The first group consisted of 48 short- and long-term survivors who underwent a complete surgical resection (5+ years follow-up). The second group consisted of 14 NSCLC patients who received 3 weeks of neo-adjuvant treatment with erlotinib prior to complete surgical resection. Response evaluation to neo-adjuvant treatment was based on histopathological examination of the surgical specimens. For both studies, kinase activity profiles of lysed cryosections of tumour tissues were generated in the presence and absence of protein tyrosine kinase inhibitors on PamChip® peptide micro-arrays, comprising 144 tyrosine containing peptides, derived from known phosphorylation sites of human proteins. Partial least square discriminant analysis was used to construct prediction models. ClustalW alignment algorithms were used to investigate the most informative phosphorylation sites. Results: Kinase activity profiles obtained in the absence of inhibitor did not distinguish between subgroups (long- versus short-term survival, responder or non-responder to TKI), whereas ratios of inhibited versus non-inhibited signals resulted in distinct classifiers predicting survival for the first group, and response for the second group. Multivariate unsupervised analysis with leave-one-out cross-validation resulted in an error rate for survival prediction of 29%. In the drug response prediction 13 out of 14 patients were correctly classified. Conclusion: This is the first study to show that kinase activity profiles of tumour tissue exposed to a kinase inhibitor can be used to identify NSCLC patients likely to respond to erlotinib treatment. Furthermore, based on kinase activity profiles of early stage NSCLC tumours, a prognostic classifier, for a set of 48 patients, was obtained. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4113. doi:10.1158/1538-7445.AM2011-4113
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 8_Supplement ( 2011-04-15), p. 4046-4046
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. 4046-4046
    Abstract: Background. In many cancers, deregulation of kinases or phosphatases leads to activation of the AKT/PKB pathway. This pathway regulates many cellular processes including metabolism, differentiation, translation, proliferation and apoptosis, so is central in determining cell fate. Several kinase inhibitors that influence AKT activity are investigated in the context of new pharmacotherapies in cancer. However, often a fraction of patients responds and it is not possible to identify those patients up front. It would be a major leap forward if response to therapy could be determined in an in vitro assay prior to the onset of therapy. Methods to directly measure this activity do not exist. In this study, we explored: 1) Whether it is feasible to determine AKT activity profiles in lysates of hyperplastic prostates of PSA-Cre;Pten-loxP/loxP mice. 2) Whether addition of AKT inhibitors affects the phosphorylation profiles in an inhibitor specific way. Methods. The PSA-Cre;Pten-loxP/loxP mouse prostate cancer model was described in Ma et al, 2005 Cancer Res 65 5730 and Korsten et al, 2009 PLoS ONE 4(5) e5662. Prostate tissues of three 4 months old PSA-Cre;Pten-loxP/loxP mice and three wt mice were lysed in buffer with protease and phosphatase inhibitors. Lysates and recombinant AKT were incubated in triplicate on PamChip® peptide micro-arrays (Folkvord et al. Int J Radiat Oncol Biol Phys. 2010 78:55) comprising 140 or 256 ser/thr containing peptides derived from known human phosphorylation sites. Peptide phosphorylation was monitored with anti- phosphoserine and anti-phosphothreonine antibodies. Incubations were performed in the presence and absence of AKT inhibitors MK2206 and AKT Inhibitor VIII. Western blotting was performed using standard methods. Blots were stained with anti-phospho-AKT antibodies and anti total AKT antibody. Results. Phosphorylation activity profiles revealed differential activity between PSA-Cre;Pten-loxP/loxP and wt mouse prostate lysates, with the Pten negative lysate having increased activity. Addition of AKT inhibitors reduced signals on several of these peptides in the prostate lysates from targeted Pten knockout mice, but not in the lysates of the wt mice. Addition of non-AKT specific inhibitors like UCN-01 resulted in signal reduction in both lysates. Western blots showed the presence of AKT in the wt lysate and in the Pten knockout lysate. Only the Pten knockout lysates contained AKT phosphorylated on S473 and T308. Conclusion. In PSA-Cre;Pten-loxP/loxP mouse prostate tissue lysate, the activity of AKT is increased compared to wild type tissue levels. The activity profiles of the PTEN/AKT pathway will support the studies on the complicated regulation of AKT activity. Up to now these studies were limited to detection of phosphoprotein abundances. This new multiplex kinase activity assay will add a new dimension and a scope of applications like drug testing. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4046. doi:10.1158/1538-7445.AM2011-4046
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 19_Supplement ( 2014-10-01), p. 5511-5511
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 5511-5511
    Abstract: Background: Regorafenib (BAY 73-4506) is the first small molecule tyrosine kinase inhibitor that has been approved for treatment of advanced CRC. In the Correct trial*, 1% of the participants showed a partial response and 42.8 % had stable disease. KRAS wild type and mutants showed equal response rates. Regorafenib is a multityrosine kinase inhibitor with nM IC50's against CRAF, VEGFR2, KIT and RET and is about tenfold less potent for BRAF, BRAFV600E, PDGFRβ and VEGFR1 and 3. We tested the effect of regorafenib and other angiogenic inhibitors on patient-derived kinases in treatment naive primary colon tumor samples for potency and selectivity of inhibition. Method: Colon tumor tissue from patients who had given informed consent was fresh frozen after surgical resection. All tumor specimens were analysed for BRAF and KRAS mutation status. Tissue cryosections were lysed in buffer with phosphatase and protease inhibitors. Phosphotyrosine kinase (PTK) and serine/threonine kinase (STK) activity profiles of tumour tissue were generated on PamChip® peptide microarrays comprising hundreds of peptide sequences derived from known human phosphorylation sites. The ex vivo effect of kinase inhibitors on these kinase activity profiles was determined. Peptide phosphorylation was monitored using fluorescently labelled antibodies. Data were analysed with Bionavigator software. Result: Kinase activity profiles were obtained from 16 CRC patient tumors for both tyrosine as well as serine/threonine specific peptide phosphorylations. Direct enzymatic inhibition of tumor-derived PTK activity was observed in all 16 samples at low micromolar concentrations (3 µM) of spiked-in regorafenib. For the serine/threonine kinase activity, spiking in of a high concentration of regorafenib (50 µM) resulted in only low levels of inhibition of phosphorylations on a subset of peptides, including BRAF substrate peptides. No difference in inhibition was observed between KRAS and BRAF mutants and wild type tumors. Furthermore the non-inhibited kinase activity profiles did not correlate to mutation status either. Conclusion: For the first time the direct biochemical effect of regorafenib has been tested on primary tumor tissue from CRC patients. These data support previous findings suggesting that regorafenib, besides its angiogenic activity on vasothelial cells, can inhibit oncogenic tyrosine kinases in the tumor. These results will be a basis for biomarker analysis by correlating on-chip drug effects to clinical responses. *Grothey et al, Lancet 2013 381(9863):303-312 Citation Format: Maria H. Hilhorst, Rosanne van den Oord, Hans Pruijt, Adriaan van den Brule, Peet Nooijen, Rik de Wijn, Liesbeth Houkes. Direct effect of regorafenib on tyrosine kinase activities in treatment naive colorectal cancer (CRC) primary tumor tissue. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5511. doi:10.1158/1538-7445.AM2014-5511
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    American Society of Clinical Oncology (ASCO) ; 2014
    In:  Journal of Clinical Oncology Vol. 32, No. 15_suppl ( 2014-05-20), p. e15572-e15572
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 32, No. 15_suppl ( 2014-05-20), p. e15572-e15572
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2014
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2010
    In:  Cancer Research Vol. 70, No. 8_Supplement ( 2010-04-15), p. 650-650
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 70, No. 8_Supplement ( 2010-04-15), p. 650-650
    Abstract: Introduction: Since treatment in oncology is rarely effective in all patients, stratification of patients with innate resistance or monitoring the emergence of acquired resistance will prevent patients being treated with ineffective drugs and will further the development of personal medicine. Several examples of such prediction methods have been reported, based on gene expression or presence of marker proteins. For kinase inhibitors, that target active kinases, it makes sense to monitor their effect on kinase activity ex vivo on a patients own tumor tissue. For the prediction of cell line response to a multityrosine kinase inhibitor (MTKI) in a proliferation assay, the feasibility of this approach has been shown, using tyrosine kinase activity profiling on a dynamic peptide microarray. Here we investigated the possibility of response prediction by profiling serine/threonine kinase activities. Methods 24 Cancer cell lines were cultured in the presence of a multi-tyrosine kinase inhibitor and the IC50 determined in a proliferation assay. Lysates from untreated cells were incubated in triplicate on a PamChip microarray comprising 140 ser/thr containing peptides in the presence and absence of hydroxystaurosporin or flavopiridol. Peptide phosphorylation by the lysates was monitored using a mixture of phosphoserine and phosphothreonine detecting antibodies. Ratios of inhibited/non-inhibited signal intensities were calculated for each peptide and correlated to the proliferation assay data. A peptide subset that gave ATP dependent signals (p & lt;0.001) was used for classification by partial least square discriminant analysis (PLS-DA). Results. As shown previously, inhibition of tyrosine phosphorylation by MTKI was able to predict response or resistance of cells both in a proliferation assay and in xenografts1). Here, phosphorylation by ser/thr kinases was investigated. Basal phosphorylation profiles obtained on the PamChip peptide microarray did not correlate with sensitivity in the proliferation assay. Using ratios of phosphorylation in the presence and absence of inhibitor hydroxystaurosporin (a PKC/PDPK inhibitor), a peptide set able to predict response in the proliferation assay was identified. More inhibition was observed in cell lines expressing an activated Akt signaling pathway. When flavopiridol (a CDK inhibitor) was used, no profile predictive of MTKI response was found. Conclusion. Peptide microarrays can be used to predict response to treatment as exemplified for cell lines in a proliferation assay. Prediction of response can be based on inhibition profiles of both tyrosine kinases activity and ser/thr kinase activity. The multiparameter readout of kinase activity links response prediction to activity of relevant signaling pathways by the appropriate choice of kinase inhibitors. 1) Versele et al. Mol Cancer Therapeutics 2009; 8(7), 1846-1855. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 650.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2010
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...